FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.

FENNEC PHARMACEUTICALS INC. Exhibit
EX-99.1 2 v475143_ex99-1.htm EXHIBIT 99.1   Exhibit 99.1   FENNEC PHARMACEUTICALS ANNOUNCES LISTING ON THE NASDAQ CAPITAL MARKET   ·          Trading on Nasdaq under the symbol "FENC" is expected to commence on September 13,…
To view the full exhibit click here

About FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF)

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) Recent Trading Information

FENNEC PHARMACEUTICALS INC. (OTCMKTS:FENCF) closed its last trading session up +3.15 at 12.00 with 15,161 shares trading hands.